Search

Displaying results 4541 - 4550 of 8700 in total
  1. Drug

    Liothyronine

    go.drugbank.com/drugs/DB00279
    ApprovedInvestigationalVet approved

    Liothyronine is a thyroidal hormone T3 which is normally produced by the thyroid gland in a ratio 4:1 when compared with T4: T3. Liothyronine is the active form of thyroxine which is composed in a basic chemical structure by a tyrosine w...

    Categories: P-glycoprotein inducers
  2. Drug

    Dengue virus serotype 2

    go.drugbank.com/drugs/DB22665
    Approved

    [L53368] Qdenga was approved for use in the European Union in December 2022.[L53373] … [A274008] It is one of four serotypes covered by Qdenga, a live, attenuated, tetravalent vaccine used for the prevention of dengue disease.

  3. Drug

    Dengue virus serotype 3

    go.drugbank.com/drugs/DB22666
    Approved

    [L53368] Qdenga was approved for use in the European Union in December 2022.[L53373] … [A274008] It is one of four serotypes covered by Qdenga, a live, attenuated, tetravalent vaccine used for the prevention of dengue disease.

  4. Drug

    Mangafodipir

    go.drugbank.com/drugs/DB06796
    ApprovedInvestigationalWithdrawn

    Mangafodipir is a contrast agent used as a diagnostic tool administered intravenously to enhance contrast in magnetic resonance imaging (MRI) of the liver and pancreas. This drug is made up of paramagnetic manganese (II) ions combined wi...

  5. Drug

    Zongertinib

    go.drugbank.com/drugs/DB18762
    ApprovedInvestigational

    [L53873,A274363] On August 8, 2025, the US FDA granted accelerated approval to zongertinib for the treatment of advanced forms of non-small cell lung cancer (NSCLC) with HER2 tyrosine kinase domain … [L53873,A274363] It covalently binds to the HER2 receptor, including exon 20 insertions, and inhibits downstream signaling pathways while sparing wild-type epidermal growth factor receptor (EGFR), which

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  6. Drug

    Lenvatinib

    go.drugbank.com/drugs/DB09078
    ApprovedInvestigational

    In particular, VEGF has been identified as a crucial regulator of both physiologic and pathologic angiogenesis and increased expression of VEGF is associated with a poor prognosis in many types of cancers … However, for patients with RAI-refractory thyroid cancer, treatment options are limited and the prognosis is poor, leading to a push for the development of more targeted therapies such as lenvatinib.

    Categories: Receptor Tyrosine Kinase Inhibitors, P-glycoprotein inhibitors
  7. Drug

    Lithium hydroxide

    go.drugbank.com/drugs/DB14506
    ApprovedWithdrawn

    Used for tryptophan determinations in proteins & foods.

  8. Drug

    Dibenzepin

    go.drugbank.com/drugs/DB13225
    Approved

    Dibenzepin is approved for use in Europe.

  9. Drug

    Gallium maltolate

    go.drugbank.com/drugs/DB05420
    Investigational

    Gallium maltolate is Titan’s novel oral agent in development for the potential treatment of chronic bacterial infections, bone disease and cancer.

  10. Drug

    MPT0B640

    go.drugbank.com/drugs/DB16512
    Investigational

    MPT0B640 was under investigation in clinical trials NCT04526717 for COVID-19 infection and NCT04294875 for locally advanced or metastatic solid malignancies.

    Categories: Experimental Unapproved Treatments for COVID-19